GBG GERMAN BREAST GROUP

PALLAS

PALLAS

PALbociclib CoLlaborative Adjuvant Study

Dr. Sabine Schmatloch

Elisabeth-Krankenhaus Kassel
Vinzenz-Verbund Hildesheim

ALLIANCE FOUNDATION TRIALS, LLC

ABCSG

BIG Breast International Group

GBG 87 - Pallas

PALbociclib CoLlaborative Adjuvant Study

A **randomized phase III trial** of **Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone** for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

GBG GERMAN BREAST GROUP

Study design

PALLAS



ALLIANCE FOUNDATION TRIALS, LLC

ABCSG

BIG Breast International Group

PALBOCICLIB



Palbociclib:

Hemmung der cyclinabhängigen Kinasen CDK4/6

GBG GERMAN BREAST GROUP

Palbociclib

PALLAS

- **Applikation:**
  125 mg/die per os,
  21 Tage, 7 Tage Pause

- **Nebenwirkungen:**
  - Neutropenie
  - Anämie, Thrombopenie
  - Infektionen
  - Fatigue
  - Nausea, Emesis
  - Diarrhoe
  - Alopezie
  - Arthralgie

Study objectives

Primary Objectives:

- To compare invasive **disease-free survival (iDFS**) for the combination of at least 5years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2-invasive early breast cancer (EBC).

Secondary Objectives:

- To compare the following endpoints:
  - **iDFS excluding second primary cancers** of nonbreast origin
  - **distant recurrence**-free survival (**DRFS**)
  - **locoregional** recurrencesfree survival (**LRRFS)**
  - overall survival (**OS**)

- To compare the **safety of 2 years of palbociclib**

Main Eligibility Criteria

Inclusion Criteria

- **Premenopausal and postmenopausal women or men** with **Stage II or Stage III** early invasive breast cancer
- Histologically confirmed **HR+, HER2-** early invasive breast cancer
- Patients must **have undergone breast surgery** for the current malignancy
- **FFPE tumor tissue block** must be transmitted to a central repository

Exclusion Criteria

- Concurrent therapy with **other IP**
- Prior therapy with **any CDK inhibitor**
- Patients with **Stage I or IV** breast cancer
- Patients receiving any medications/ substances that are **potent inhibitors or inducers of CYP3A** isoenzymes within 7 days of randomization

Study Phases

Screening Phase (up to 30 days)

- Time between the date a **patient provides written informed consent** and the time the **patient completes randomization**

Treatment Phase (2 years)

- **Arm A:** Palbociclib (26 cycles of 28 days) + Endocrine Treatment
- **Arm B:** Endocrine Treatment

Follow Up Phase 1 (years 3 through 5)

- Visits **every 6 months**, Non-IP Therapy (Endocrine Treatment) allowed, no IP given

Follow Up Phase 2 (years 6 through 10)

- **Annual collection of patient status/information**, no IP given, follow up even if endocrine therapy is permanently discontinued

GBG GERMAN BREAST GROUP

Recruitment Non-US 24 Feb 2017

PALLAS



GBG GERMAN BREAST GROUP

Timelines

PALLAS

US Sponsor	ALLIANCE Foundation Trials (AFT), LLC.
Ex-US Sponsor:	Austrian Breast & Colorectal Cancer Study Group
Sites in Germany:	35
Study start Germany :	QII 2017
First Patient In (global):	01.09.2015
First Patient in (Non-US):	28.10.2015
Total	846 randomized (369 stage IIA)
Non-US:	319 randomized (164 stage IIA)
US:	547 randomized (185 stage IIA)
Last Patient In:	September 2018
First interim analysis:	<3 years after FPI
Final analysis:	<4 years after FPI

ALLIANCE FOUNDATION TRIALS, LLC ABCSG BIG Breast International Group

Lokales deutsches Amendment

- **Konditionale BfArM Genehmigung am 12. Oktober 2016**
  - **Angeforderte Änderungen**
    - **Ausschluss von Patienten mit QTcF > 480 ms bei Screening**
    - **Durchführung eines Kontroll EKGs bei Screening und an Tag 14 Zyklus 1**
    - **Aktualisierung der klinischen Daten auf neuesten Stand**
  - **Lokales deutsches Amendent freigegeben von Sponsor: 20. Januar 2017**
  - **Amendment liegt aktuell zur Bewertung bei Ethik und BfArM**
- **Zentrenstatus:**
  - **Rückmeldung zu Studienvertrag an GBG (falls ausstehend) bis 17. März**
  - **Durchführung von internetbasierten CRF und IWRS Training durch Studienpersonal (notwendig für Aktivierung)**

  → Kontaktieren Sie das Studienteam wenn Ihnen kein Trainingslink vorliegt

Contact

Leiter der Klinischen Prüfung:

Dr. Sabine Schmatloch
Elisabeth Krankenhaus Kassel
s.schmatloch@vinzenz-verbund.de

Durchführung in Deutschland:

GBG Forschungs GmbH
Dr. Christian Mäurer
pallas@GBG.de

GBG
GERMAN
BREAST
GROUP

Vielen Dank für Ihre Aufmerksamkeit!



GBG

GERMAN
BREAST
GROUP

GBG
GERMAN
BREAST
GROUP

ANATOMIC STAGE/PROGNOSTIC GROUPS			
Stage 0	Tis	N0	M0
Stage IA	T1*	N0	M0
Stage IB	T0	N1mi	M0
	T1*	N1mi	M0
Stage IIA	T0	N1**	M0
	T1*	N1**	M0
	T2	N0	M0
Stage IIB	T2	N1	M0
	T3	N0	M0
Stage IIIA	T0	N2	M0
	T1*	N2	M0
	T2	N2	M0
	T3	N1	M0
	T3	N2	M0
Stage IIIB	T4	N0	M0
	T4	N1	M0
	T4	N2	M0
Stage IIIC	Any T	N3	M0